Central Exclusive Production in QCD

We investigate the theoretical description of the central exclusive production process, h1+h2 -> h1+X+h2. Taking Higgs production as an example, we sum logarithmically enhanced corrections appearing in the perturbation series to all orders in the strong coupling. Our results agree with those originally presented by Khoze, Martin and Ryskin except that the scale appearing in the Sudakov factor, mu=0.62 \sqrt{\hat{s}}, should be replaced with mu=\sqrt{\hat{s}}, where \sqrt{\hat{s}} is the invariant mass of the centrally produced system. We confirm this result using a fixed-order calculation and show that the replacement leads to approximately a factor 2 suppression in the cross-section for central system masses in the range 100-500 GeV.Comment: 41 pages, 19 figures; minor typos fixed; version published in JHE

The Spin Structure of the Nucleon

We present an overview of recent experimental and theoretical advances in our understanding of the spin structure of protons and neutrons.Comment: 84 pages, 29 figure

Clinical Recommendations for the Diagnosis and Treatment of Chronic Myeloid Leukemia

This article is the 4th edition of the recommendations for the diagnosis and treatment of chronic myeloid leukemia. The group of authors reviewed and discussed relevant new publications, and included the significant remarks and comments of experts. Particular attention was paid to the control of risk factors for the development of arterial vascular events and their prevention, and adverse effects of the long-term therapy with tyrosine kinase inhibitors, which were being increasingly reported in recent years

Chronic Myeloid Leukemia Patient Registry in the Russian Federation: From Observational Studies to the Efficacy Evaluation in Clinical Practice

Background. Due to the significant increase in life expectancy and the quality of life in patients with chronic myeloid leukemia (CML) as well as the growing need for expensive tyrosine kinase inhibitors (TKI), the analysis of cost-effectiveness and lifelong monitoring of patients is especially important. Aim. We present the results of a multicenter observational study “The Russian Registry of Chronic Myeloid Leukemia in routine clinical practice (2011–2016)”. Materials & Methods. The study included Russian patients with CML, confirmed by the detection of a Ph-chromosome or a BCR-ABL transcript. The statistical analysis (July 1, 2016) included 7609 patients from 80 regions of the Russian Federation (covering 95 % of the population). The annual increase in the number of patients with newly diagnosed CML was 600–650 patients. At the time of the statistical analysis, 6995 (92 %) patients remained under observation, 473 (6 %) died and 141 (2 %) were withdrawn. The registry included 44 % of men and 56 % of women, the median age was 49 years (range 2–94 years). The peak incidence (46.3 %) occurred at the age of 40–60 years. The median disease duration by the time of the analysis was 6 years (range 0.1–30 years). Results. The disease was diagnosed in the chronic phase (CP), acceleration phase, and blast crisis in 6560 (93.8 %), 380 (5.5 %) and 47 (0.7 %) patients, respectively. The proportion of risk groups according to Sokal for low, intermediate and high risk in CP was 49 %, 30 %, and 21 %, respectively. TKI were administered to 6473 (92.5 %) patients. Imatinib and the second generation TKI (TKI2) were administered to 5570 (86 %) and 903 (14 %) patients, respectively. The total of 30.4 % of patients received the increased imatinib dose of 600–800 mg. In the TKI2 group, 558 (61.7 %) patients received nilotinib and 345 (38.2 %) patients received dasatinib. The proportion of patients with completed molecular genetic studies (MGS) in 2014, 2015 and the first 6 months of 2016 amounted to 61 %, 58 % and 23 %, respectively. The proportion of patients with cytogenetic studies (CS) for the same period was 28 %, 26 % and 7 %, respectively. No CS or MGS data were presented for 34 %, 35 % and 63 % of patients during this period. Optimal molecular response and major molecular response (MMR) for TKI therapy were observed in 23 % and 58 % of patients treated 12 months, respectively. When nilotinib was used in the second line, MMR was obtained in 42 % of patients, and a deep molecular response was obtained in 25 % of patients (BCR-ABL < 0.01 %). Conclusion. The high efficacy of TKI therapy was observed in the majority of patients with the possibility of achieving a minimal residual disease. The problems concerning untimely monitoring and suboptimal administration of second line treatment were identified. In general, the CML patient registry allowed the data integration of data and information management of population with CML in Russia

Collaborative Enhancement of Antibody Binding to Distinct PECAM-1 Epitopes Modulates Endothelial Targeting

Antibodies to platelet endothelial cell adhesion molecule-1 (PECAM-1) facilitate targeted drug delivery to endothelial cells by “vascular immunotargeting.” To define the targeting quantitatively, we investigated the endothelial binding of monoclonal antibodies (mAbs) to extracellular epitopes of PECAM-1. Surprisingly, we have found in human and mouse cell culture models that the endothelial binding of PECAM-directed mAbs and scFv therapeutic fusion protein is increased by co-administration of a paired mAb directed to an adjacent, yet distinct PECAM-1 epitope. This results in significant enhancement of functional activity of a PECAM-1-targeted scFv-thrombomodulin fusion protein generating therapeutic activated Protein C. The “collaborative enhancement” of mAb binding is affirmed in vivo, as manifested by enhanced pulmonary accumulation of intravenously administered radiolabeled PECAM-1 mAb when co-injected with an unlabeled paired mAb in mice. This is the first demonstration of a positive modulatory effect of endothelial binding and vascular immunotargeting provided by the simultaneous binding a paired mAb to adjacent distinct epitopes. The “collaborative enhancement” phenomenon provides a novel paradigm for optimizing the endothelial-targeted delivery of therapeutic agents

Chi(c) decays and the gluon component of the eta', eta mesons

The large mass of the η′meson indicates that a sizeable gluon component is present in the meson wave function. However, the χc0and χc2decays to η′mesons, which proceed via a purely gluonic intermediate state and we would therefore naïvely expect to be enhanced by such a component, are in fact relatively suppressed. We argue that this apparent contradiction may be resolved by a proper treatment of interference effects in the decay. In particular, by accounting for the destructive interference between the quark and gluon components of the η′distribution function, in combination with a model for strange quark mass effects, we demonstrate that the observed χc(0,2)→η(′)η(′) branching ratios can be reproduced for a reasonable gluon component of the η′, η mesons

A magnetic non-reciprocal isolator for broadband terahertz operation

A Faraday isolator is an electromagnetic non-reciprocal device, a key element in photonics. It is required to shield electromagnetic sources against the effect of back-reflected light, as well as to limit the detrimental effect of back-propagating spontaneous emissions. A common isolator variant, the circulator, is widely used to obtain a complete separation between forward- and backward-propagating waves, thus enabling the realization of a desired transfer function in reflection only. Here we demonstrate a non-reciprocal terahertz Faraday isolator, operating on a bandwidth exceeding one decade of frequency, a necessary requirement to achieve isolation with the (few-cycle) pulses generated by broadband sources. The exploited medium allows a broadband rotation, up to 194�/T, obtained using a SrFe12O19 terahertz transparent permanent magnet. This in turn enables the design of a stand-alone complete terahertz isolator without resorting to an external magnetic field bias, as opposed to all the optical isolators realized so far